MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$347,166
EPS
-$0.09
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development
-518,168 697,723 3,785,649 3,975,522*
General and administrative
1,687,403 2,126,918 1,867,040 1,719,467.5*
Restructuring costs
42,414 1,236,172 --
Total operating expenses
1,211,649 4,060,813 5,652,689 5,694,989.5*
(loss) income from operations
-1,211,649 -4,060,813 -5,652,689 -13,539,614*
Interest income, net
186,171 167,311 141,996 101,464*
(loss) gain on foreign currency transactions
-291,522 -135,659 -61,735 -1,618,666.5*
Research and development incentive award
-341,951 -478,959 -151,604*
Gain (loss) on fair value adjustments
435,193 5,379,500 -4,368,869 496,570*
Total other income (expense)
671,793 5,890,111 -4,288,608 -1,172,236.5*
(loss) income before income taxes
-539,856 1,829,298 -9,941,297 -14,711,850.5*
Income tax benefit
-34,793 -34,794 -34,793 -364,000.5*
Net (loss) income
-505,063 1,864,092 -9,906,504 -14,347,850*
Unrealized gain (loss) on foreign currency translation
157,897 570,580 49,221 2,394,905.5
Total other comprehensive income (loss)
157,897 570,580 49,221 2,394,905.5*
Total comprehensive income (loss)
-347,166 2,434,672 -9,857,283 -11,952,944.5
Basic EPS
-0.09 0.41 -4.41 -7.592
Diluted EPS
-0.09 -0.77 -4.41 -7.592
Basic Average Shares
5,411,244 4,536,235 2,246,066 1,574,455
Diluted Average Shares
5,411,244 4,536,235 2,246,066 1,574,455
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Unrealized gain (loss) onforeign currency...$157,897 (180.63%↑ Y/Y)Total comprehensiveincome (loss)-$347,166 (-103.14%↓ Y/Y)Total othercomprehensive income (loss)$157,897 (180.63%↑ Y/Y)Net (loss) income-$505,063 (-104.48%↓ Y/Y)Income tax benefit-$34,793 (57.14%↑ Y/Y)Gain (loss) on fairvalue adjustments$435,193 (144.56%↑ Y/Y)Research and developmentincentive award-$341,951 (-6642.01%↓ Y/Y)Interest income, net$186,171 (1361.20%↑ Y/Y)(loss) income beforeincome taxes-$539,856 (-104.83%↓ Y/Y)Total other income(expense)$671,793 (184.37%↑ Y/Y)(loss) gain on foreigncurrency transactions-$291,522 (-268.56%↓ Y/Y)(loss) income fromoperations-$1,211,649 (-110.12%↓ Y/Y)Total operatingexpenses$1,211,649 (-59.92%↓ Y/Y)Research and development-$518,168 (-132.06%↓ Y/Y)General andadministrative$1,687,403 (19.95%↑ Y/Y)Restructuring costs$42,414

Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Inc. (NEUP)